These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 31748013)

  • 21. Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments.
    Aggio FB; Farah ME; Silva WC; Melo GB
    Graefes Arch Clin Exp Ophthalmol; 2007 Feb; 245(2):215-20. PubMed ID: 17139490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Photodynamic therapy with verteporfin for choroidal neovascularization in patients with diabetic retinopathy.
    Ladd BS; Solomon SD; Bressler NM; Bressler SB
    Am J Ophthalmol; 2001 Nov; 132(5):659-67. PubMed ID: 11704027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequence of early vascular events after photodynamic therapy.
    Michels S; Schmidt-Erfurth U
    Invest Ophthalmol Vis Sci; 2003 May; 44(5):2147-54. PubMed ID: 12714655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone.
    Augustin AJ; Puls S; Offermann I
    Retina; 2007 Feb; 27(2):133-40. PubMed ID: 17290193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
    Brown DM; Michels M; Kaiser PK; Heier JS; Sy JP; Ianchulev T;
    Ophthalmology; 2009 Jan; 116(1):57-65.e5. PubMed ID: 19118696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Experimental photodynamic effects of hypocrellin A on the choriocapillaris.
    Khoobehi B; Grinstead R; Passos E
    Ophthalmic Surg Lasers; 2002; 33(3):207-13. PubMed ID: 12027100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of verteporfin photodynamic therapy on endostatin and angiogenesis in human choroidal neovascular membranes.
    Tatar O; Shinoda K; Adam A; Eckert T; Eckardt C; Lucke K; Deuter C; Bartz-Schmidt KU; Grisanti S
    Br J Ophthalmol; 2007 Feb; 91(2):166-73. PubMed ID: 16987895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive role of coagulation-balance gene polymorphisms in the efficacy of photodynamic therapy with verteporfin for classic choroidal neovascularization secondary to age-related macular degeneration.
    Parmeggiani F; Costagliola C; Gemmati D; D'Angelo S; Perri P; Scapoli GL; Catozzi L; Federici F; Sebastiani A; Incorvaia C
    Pharmacogenet Genomics; 2007 Dec; 17(12):1039-46. PubMed ID: 18004208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathologic studies of age-related macular degeneration with classic subfoveal choroidal neovascularization treated with photodynamic therapy.
    Ghazi NG; Jabbour NM; De La Cruz ZC; Green WR
    Retina; 2001; 21(5):478-86. PubMed ID: 11642377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. One-year follow-up of combined customized therapy. Photodynamic therapy and bevacizumab for exudative age-related macular degeneration.
    Navea A; Mataix J; Desco MC; Garcia-Pous M; Palacios E
    Retina; 2009 Jan; 29(1):13-9. PubMed ID: 18854782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.
    Kaiser PK; ; Boyer DS; Garcia R; Hao Y; Hughes MS; Jabbour NM; Kaiser PK; Mieler W; Slakter JS; Samuel M; Tolentino MJ; Roth D; Sheidow T; Strong HA
    Ophthalmology; 2009 Apr; 116(4):747-55, 755.e1. PubMed ID: 19243834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration.
    Lazic R; Gabric N
    Ophthalmology; 2007 Jun; 114(6):1179-85. PubMed ID: 17544776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada.
    Earnshaw SR; Moride Y; Rochon S
    Clin Ther; 2007 Sep; 29(9):2096-106; discussion 2094-5. PubMed ID: 18035208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Photodynamic-induced vascular damage of the chick chorioallantoic membrane model using perylenequinones.
    Chin W; Lau W; Lay SL; Wei KK; Olivo M
    Int J Oncol; 2004 Oct; 25(4):887-91. PubMed ID: 15375536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vascular-targeted photodynamic therapy in the treatment of neovascular age-related macular degeneration: Clinical perspectives.
    Kawczyk-Krupka A; Bugaj AM; Potempa M; Wasilewska K; Latos W; Sieroń A
    Photodiagnosis Photodyn Ther; 2015 Jun; 12(2):161-75. PubMed ID: 25843911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The treatment of the exsudative age-related macular degeneration with choroidal neovascular membrane, its possibilities and economical indexes].
    Karel I
    Cesk Slov Oftalmol; 2007 Sep; 63(5):311-9. PubMed ID: 17915581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of verteporfin for treatment of subfoveal choroidal neovascular membranes associated with age-related macular degeneration.
    Gaynes BI; Fiscella RG
    Expert Opin Drug Saf; 2004 Jul; 3(4):345-61. PubMed ID: 15268651
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Photodynamic therapy with verteporfin in occult choroidal neovascularization in age-related macular degeneration].
    Kürzinger GR; Stender B; Lang GK; Lang GE
    Klin Monbl Augenheilkd; 2010 Jun; 227(6):501-6. PubMed ID: 20349399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preserving vision with verteporfin photodynamic therapy.
    Yang YC
    Hosp Med; 2004 Jan; 65(1):39-43. PubMed ID: 14964795
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy.
    Tatar O; Adam A; Shinoda K; Stalmans P; Eckardt C; Lüke M; Bartz-Schmidt KU; Grisanti S
    Am J Ophthalmol; 2006 Jul; 142(1):95-104. PubMed ID: 16815256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.